You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America and explain in detail?
The ACC and AHA have developed evidence-based guidelines to improve quality of care and align with patient interests. This focused update reassesses existing guideline recommendations on pharmacological therapy for heart failure with reduced ejection fraction, based on recently published study data. The document covers topics such as angioedema, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, beta blockers, ivabradine, and natriuretic peptides. The guidelines are reviewed annually by the ACC/AHA Task Force and are official policy.